Regulatory activity of azabisphosphonate-capped dendrimers on human CD4+ T cell proliferation enhances ex-vivo expansion of NK cells from PBMCs for immunotherapy

详细信息    查看全文

• 作者：Damien Portevin (1) (2)
  Mary Poupot (1) (2)
  Olivier Rolland (3) (4)
  Cédric-Olivier Turrin (3) (4)
  Jean-Jacques Fournié (1) (2)
  Jean-Pierre Majoral (3) (4)
  Anne-Marie Caminade (3) (4)
  Remy Poupot (1) (2)
  
• 刊名：Journal of Translational Medicine
• 出版年：2009
• 出版时间：December 2009
• 年：2009
• 卷：7
• 期：1
• 全文大小：2059KB
• 参考文献：1. Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA, Breso V, Frassati C, Reviron D, Middleton D, / et al.: Human NK cell education by inhibitory receptors for MHC class I. / Immunity 2006, 25:331-42. CrossRef
  2. Cooper MA, Fehniger TA, Caligiuri MA: The biology of human natural killer-cell subsets. / Trends Immunol 2001, 22:633-40. CrossRef
  3. Poli A, Michel T, Theresine M, Andres E, Hentges F, Zimmer J: CD56bright natural killer (NK) cells: an important NK cell subset. / Immunology 2009, 126:458-65. CrossRef
  4. Kiessling R, Klein E, Wigzell H: "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. / Eur J Immunol 1975, 5:112-17. CrossRef
  5. Karre K: NK cells, MHC class I molecules and the missing self. / Scand J Immunol 2002, 55:221-28. CrossRef
  6. Karre K: Natural killer cell recognition of missing self. / Nat Immunol 2008, 9:477-80. CrossRef
  7. Lanier LL: NK cell recognition. / Annu Rev Immunol 2005, 23:225-74. CrossRef
  8. Uhrberg M: Shaping the human NK cell repertoire: an epigenetic glance at KIR gene regulation. / Mol Immunol 2005, 42:471-75. CrossRef
  9. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, / et al.: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. / Science 2002, 295:2097-100. CrossRef
  10. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, Stern M, Pende D, Perruccio K, Burchielli E, / et al.: Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. / Blood 2007, 110:433-40. CrossRef
  11. Lundqvist A, McCoy JP, Samsel L, Childs R: Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors. / Blood 2007, 109:3603-606. CrossRef
  12. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, / et al.: Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. / Blood 2005, 105:3051-057. CrossRef
  13. Malmberg KJ, Bryceson YT, Carlsten M, Andersson S, Bjorklund A, Bjorkstrom NK, Baumann BC, Fauriat C, Alici E, Dilber MS, Ljunggren HG: NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy. / Cancer Immunol Immunother 2008, 57:1541-552. CrossRef
  14. Ruggeri L, Mancusi A, Perruccio K, Burchielli E, Martelli MF, Velardi A: Natural killer cell alloreactivity for leukemia therapy. / J Immunother 2005, 28:175-82. CrossRef
  15. Alici E, Sutlu T, Bjorkstrand B, Gilljam M, Stellan B, Nahi H, Quezada HC, Gahrton G, Ljunggren HG, Dilber MS: Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. / Blood 2008, 111:3155-162. CrossRef
  16. Medina SH, El-Sayed ME: Dendrimers as Carriers for Delivery of Chemotherapeutic Agents. / Chem Rev 2009, 109:3141-157. CrossRef
  17. Vannucci L, Fiserova A, Sadalapure K, Lindhorst TK, Kuldova M, Rossmann P, Horvath O, Kren V, Krist P, Bezouska K, / et al.: Effects of N-acetyl-glucosamine-coated glycodendrimers as biological modulators in the B16F10 melanoma model in vivo. / Int J Oncol 2003, 23:285-96.
  18. Sheng KC, Kalkanidis M, Pouniotis DS, Esparon S, Tang CK, Apostolopoulos V, Pietersz GA: Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo. / Eur J Immunol 2008, 38:424-36. CrossRef
  19. Poupot M, Griffe L, Marchand P, Maraval A, Rolland O, Martinet L, L'Faqihi-Olive FE, Turrin CO, Caminade AM, Fournie JJ, / et al.: Design of phosphorylated dendritic architectures to promote human monocyte activation. / Faseb J 2006, 20:2339-351. CrossRef
  20. Rolland O, Griffe L, Poupot M, Maraval A, Ouali A, Coppel Y, Fournie JJ, Bacquet G, Turrin CO, Caminade AM, / et al.: Tailored control and optimisation of the number of phosphonic acid termini on phosphorus-containing dendrimers for the ex-vivo activation of human monocytes. / Chemistry 2008, 14:4836-850. CrossRef
  21. Fruchon S, Poupot M, Martinet L, Turrin CO, Majoral JP, Fournie JJ, Caminade AM, Poupot R: Anti-inflammatory and immunosuppressive activation of human monocytes by a bioactive dendrimer. / J Leukoc Biol 2009, 85:553-62. CrossRef
  22. Griffe L, Poupot M, Marchand P, Maraval A, Turrin CO, Rolland O, Metivier P, Bacquet G, Fournie JJ, Caminade AM, / et al.: Multiplication of human natural killer cells by nanosized phosphonate-capped dendrimers. / Angew Chem Int Ed Engl 2007, 46:2523-526. CrossRef
  23. Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, Chaput N, Puig PE, Novault S, Escudier B, Vivier E, / et al.: CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. / J Exp Med 2005, 202:1075-085. CrossRef
  24. Ralainirina N, Poli A, Michel T, Poos L, Andres E, Hentges F, Zimmer J: Control of NK cell functions by CD4+CD25+ regulatory T cells. / J Leukoc Biol 2007, 81:144-53. CrossRef
  25. Thornton AM, Donovan EE, Piccirillo CA, Shevach EM: Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. / J Immunol 2004, 172:6519-523.
  26. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, / et al.: CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. / J Exp Med 2006, 203:1701-711. CrossRef
  27. Carlens S, Gilljam M, Chambers BJ, Aschan J, Guven H, Ljunggren HG, Christensson B, Dilber MS: A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells. / Hum Immunol 2001, 62:1092-098. CrossRef
  28. Jin Y, Knudsen E, Wang L, Bryceson Y, Damaj B, Gessani S, Maghazachi AA: Sphingosine 1-phosphate is a novel inhibitor of T-cell proliferation. / Blood 2003, 101:4909-915. CrossRef
  29. Miller JS, Oelkers S, Verfaillie C, McGlave P: Role of monocytes in the expansion of human activated natural killer cells. / Blood 1992, 80:2221-229.
  30. Dunne J, Lynch S, O'Farrelly C, Todryk S, Hegarty JE, Feighery C, Doherty DG: Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15. / J Immunol 2001, 167:3129-138.
  31. Walker MR, Kasprowicz DJ, Gersuk VH, Benard A, Van Landeghen M, Buckner JH, Ziegler SF: Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. / J Clin Invest 2003, 112:1437-443.
  32. Klenerman P, Cerundolo V, Dunbar PR: Tracking T cells with tetramers: new tales from new tools. / Nat Rev Immunol 2002, 2:263-72. CrossRef
  33. Poupot M, Fournie JJ: Non-peptide antigens activating human Vgamma9/Vdelta2 T lymphocytes. / Immunol Lett 2004, 95:129-38. CrossRef
  34. Mestel DS, Assaf C, Steinhoff M, Beyer M, Moebs M, Sterry W: Emerging drugs in cutaneous T cell lymphoma. / Expert Opin Emerg Drugs 2008, 13:345-61. CrossRef
  
• 作者单位：Damien Portevin (1) (2)
  Mary Poupot (1) (2)
  Olivier Rolland (3) (4)
  Cédric-Olivier Turrin (3) (4)
  Jean-Jacques Fournié (1) (2)
  Jean-Pierre Majoral (3) (4)
  Anne-Marie Caminade (3) (4)
  Remy Poupot (1) (2)
  
  1. INSERM, U.563, Centre de Physiopathologie de Toulouse-Purpan, F-31300, Toulouse, France
  2. Université Paul-Sabatier, F-31300, Toulouse, France
  3. CNRS, LCC (Laboratoire de Chimie de Coordination), 205, route de Narbonne, F-31077, Toulouse, France
  4. UPS, INPT; LCC, Université de Toulouse, 205, route de Narbonne, F-31077, Toulouse, France
  

文摘

Background Adoptive cell therapy with allogenic NK cells constitutes a promising approach for the treatment of certain malignancies. Such strategies are currently limited by the requirement of an efficient protocol for NK cell expansion. We have developed a method using synthetic nanosized phosphonate-capped dendrimers allowing such expansion. We are showing here that this is due to a specific inhibitory activity towards CD4+ T cell which could lead to further medical applications of this dendrimer. Methods Mononuclear cells from human peripheral blood were used to investigate the immunomodulatory effects of nanosized phosphonate-capped dendrimers on interleukin-2 driven CD4+T cell expansion. Proliferation status was investigated using flow cytometry analysis of CFSE dilution and PI incorporation experiments. Magnetic bead cell sorting was used to address activity towards individual or mixed cell sub-populations. We performed equilibrium binding assay to assess the interaction of fluorescent dendrimers with pure CD4+ T cells. Results Phosphonate-capped dendrimers are inhibiting the activation, and therefore the proliferation; of CD4+ T cells in IL-2 stimulated PBMCs, without affecting their viability. This allows a rapid enrichment of NK cells and further expansion. We found that dendrimer acts directly on T cells, as their regulatory property is maintained when stimulating purified CD4+ T cells with anti-CD3/CD28 microbeads. Performing equilibrium binding assays using a fluorescent analogue, we show that the phosphonate capped-dendrimers are specifically interacting with purified CD4+ T cells. Ultimately, we found that our protocol prevents the IL-2 related expansion of regulatory T cells that would be deleterious for the activity of infused NK cells. Conclusion High yield expansion of NK cells from human PBMCs by phosphonate-capped dendrimers and IL-2 occurs through the specific inhibition of the CD4+ lymphocyte compartment. Given the specificity of the interaction of dendrimers with CD4+ T cell, we hypothesize that regulatory activity may signal through a specific receptor that remains to be indentified. Therefore phosphonate-capped dendrimers constitute not only tools for the ex-vivo expansion of NK cells in immunotherapy of cancers but their mode of action could also lead to further medical applications where T cell activation and proliferation need to be dampened.